{"title": "JPM 2022: Vertex's Trikafta holds the line as company lays groundwork for gene editing launch", "author": "Fraiser Kansteiner", "url": "https://www.fiercepharma.com/pharma/vertex-s-trikafta-holds-line-as-company-lays-groundwork-for-gene-editing-launch", "hostname": "fiercepharma.com", "description": "Vertex Pharmaceuticals is well known for its slew of cystic fibrosis medications, and newcomer Trikafta is pulling its weight. | Vertex Pharmaceuticals is well known for its slew of cystic fibrosis medications, and newcomer Trikafta is pulling its weight. Over the course of 2021, the med clinched reimbursement in 16 countries and launched for kids ages 6 to 11 in the U.S.", "sitename": "FiercePharma", "date": "2022-01-10", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}